Trial Profile
Pilot trial of a WT-1 analog peptide vaccine in patients with thoracic and myeloid neoplasms
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs INNO 305 (Primary) ; Montanide ISA-51; Sargramostim
- Indications Acute myeloid leukaemia; Malignant-mesothelioma; Mesothelioma; Myelodysplastic syndromes; Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 15 Jan 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 10 Jan 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 31 Oct 2006 New trial record.